Lencaneluzumab biosimilar approved for clinical trials for the treatment of Alzheimer’s disease
October 3, 2025
Source: drugdu
78
Sinopharm announced that its subsidiary, Jushi Biopharmaceuticals Co., Ltd., of CSPC Pharmaceutical Group, has received the "Notice of Approval for Clinical Trial of Lencanelumab Injection" from the National Medical Products Administration (NMPA). Clinical trials of the drug will commence soon. Lencanelumab Injection is a recombinant anti-human amyloid-β monoclonal antibody and a biosimilar to Leyibao, indicated for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease.
The product approved for clinical trials by Sinopharm is the first biosimilar to lencanelumab injection to obtain clinical approval in China .
Currently, there are only a handful of new Alzheimer's disease drugs on the market, such as Lencaneluzumab and Donezetimumab, all developed by multinational pharmaceutical companies and relatively expensive. The clinical approval of domestically produced biosimilars suggests the potential for improved patient accessibility and reduced financial burdens in the future.
Source: https://cj.sina.cn/articles/view/5953189932/162d6782c06703893e?froms=ggmp
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
